Skip to content
Review

Uterine Cervix Cancer—20-Year Comparative Mortality and Survival Analysis by Age, Race/Ethnicity, Stage, Grade, Disease Duration, Selected ICD-O-3 Histologic Oncophenotypes, and Cohort Entry Time Period: A Systematic Review of 45,213 Cases for Diagnosis Years 1975-2023

Oct 2026 · Journal of Insurance Medicine · 0 citations · 16 references

Abstract

.—Globally, cervical cancer is the fourth most common cancer in women with 604,127 new cases and 341,837 related deaths in 2022. The primary risk factor for cervical cancer is human papillomavirus (HPV) infection, especially by HPV subtypes 16 and 18. In 2019, HPV caused an estimated 620,000 cancer cases in women and 70,000 cancer cases in men. .—This research study is a comparative, systematic, and integrated population-based medical-actuarial risk analysis of cervical cancer mortality and survival by age, race and ethnicity, stage, grade, disease duration, and histologic subtypes in 2 cohort entry periods: 1975-1999 and 2000-2023. Using the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) 8 Registry as of April 27, 2026, 45,213 primary cases of malignant cervical cancer were selected. The following 2 staging systems were used for comparison: the traditional SEER historic stage A (local, regional, and distant stages) in use since 1973 and the new version 9 American Joint Committee on Cancer tumor, node, metastasis staging system for cervical cancer, with the latter system providing a strategy for specific grouping of patients with respect to prognosis and treatment. .—This research study presents uterine cervix cancer epidemiologic aspects of incidence and mortality and survival, as well as medical-actuarial analytic outcomes by disease duration, extent and severity of disease, histologic variants, and cohort entry period over 20 years. .—Unlike most malignancies, the morbidity and mortality rates due to cervical cancer were found to have not improved but slightly worsened for the 2000-2023 cohort compared with the 1975-1999 cohort. Evidence suggests that, possibly because of socioeconomic factors, there is failure of timely cancer screening in many middle-aged women. Timely HPV vaccination seems to offer the best risk factor protection for disease prevention and amelioration.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.